Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 154

Similar articles for PubMed (Select 24180002)

1.

Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype.

McIlleron HM, Schomaker M, Ren Y, Sinxadi P, Nuttall JJ, Gous H, Moultrie H, Eley B, Merry C, Smith P, Haas DW, Maartens G.

AIDS. 2013 Jul 31;27(12):1933-40.

2.

Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia.

Bertrand J, Verstuyft C, Chou M, Borand L, Chea P, Nay KH, Blanc FX, Mentré F, Taburet AM; CAMELIA (ANRS 1295-CIPRA KH001) Study Group.

J Infect Dis. 2014 Feb 1;209(3):399-408. doi: 10.1093/infdis/jit466. Epub 2013 Aug 29.

3.

Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy.

Lee KY, Lin SW, Sun HY, Kuo CH, Tsai MS, Wu BR, Tang SY, Liu WC, Chang SY, Hung CC.

PLoS One. 2014 Feb 14;9(2):e88497. doi: 10.1371/journal.pone.0088497. eCollection 2014.

4.

Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa.

Cohen K, Grant A, Dandara C, McIlleron H, Pemba L, Fielding K, Charalombous S, Churchyard G, Smith P, Maartens G.

Antivir Ther. 2009;14(5):687-95.

5.

Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.

Manosuthi W, Sukasem C, Lueangniyomkul A, Mankatitham W, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S.

Antimicrob Agents Chemother. 2013 Feb;57(2):1019-24. doi: 10.1128/AAC.02023-12. Epub 2012 Dec 17.

6.

Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.

Mukonzo JK, Okwera A, Nakasujja N, Luzze H, Sebuwufu D, Ogwal-Okeng J, Waako P, Gustafsson LL, Aklillu E.

BMC Infect Dis. 2013 Jun 4;13:261. doi: 10.1186/1471-2334-13-261.

7.

CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India.

Ramachandran G, Hemanth Kumar AK, Rajasekaran S, Kumar P, Ramesh K, Anitha S, Narendran G, Menon P, Gomathi C, Swaminathan S.

Antimicrob Agents Chemother. 2009 Mar;53(3):863-8. doi: 10.1128/AAC.00899-08. Epub 2009 Jan 5.

8.

CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.

Kwara A, Lartey M, Sagoe KW, Rzek NL, Court MH.

Br J Clin Pharmacol. 2009 Apr;67(4):427-36. doi: 10.1111/j.1365-2125.2009.03368.x.

9.

The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients.

Bienvenu E, Swart M, Dandara C, Ashton M.

Antiviral Res. 2014 Feb;102:44-53. doi: 10.1016/j.antiviral.2013.11.011. Epub 2013 Dec 5.

PMID:
24316028
10.

Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.

Boulle A, Van Cutsem G, Cohen K, Hilderbrand K, Mathee S, Abrahams M, Goemaere E, Coetzee D, Maartens G.

JAMA. 2008 Aug 6;300(5):530-9. doi: 10.1001/jama.300.5.530.

PMID:
18677025
11.

Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation.

Kwara A, Lartey M, Sagoe KW, Xexemeku F, Kenu E, Oliver-Commey J, Boima V, Sagoe A, Boamah I, Greenblatt DJ, Court MH.

J Clin Pharmacol. 2008 Sep;48(9):1032-40. doi: 10.1177/0091270008321790.

12.

A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.

Manosuthi W, Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, Prasithsirskul W, Burapatarawong S, Thongyen S, Likanonsakul S, Thawornwa U, Prommool V, Ruxrungtham K; N2R Study Team.

Clin Infect Dis. 2009 Jun 15;48(12):1752-9. doi: 10.1086/599114.

13.

Mid-dosing interval efavirenz plasma concentrations in HIV-1-infected children in Rwanda: treatment efficacy, tolerability, adherence, and the influence of CYP2B6 polymorphisms.

Mutwa PR, Fillekes Q, Malgaz M, Tuyishimire D, Kraats Rv, Boer KR, Burger DM, van Schaik RH, Muganga N, Geelen SP.

J Acquir Immune Defic Syndr. 2012 Aug 1;60(4):400-4. doi: 10.1097/QAI.0b013e3182569f57.

PMID:
22481606
14.

CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1.

Manosuthi W, Sukasem C, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S.

Antimicrob Agents Chemother. 2014;58(4):2268-73. doi: 10.1128/AAC.02384-13. Epub 2014 Feb 3.

15.

In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype.

Rekić D, Röshammar D, Mukonzo J, Ashton M.

Br J Clin Pharmacol. 2011 Apr;71(4):536-43. doi: 10.1111/j.1365-2125.2010.03883.x.

16.

Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis.

Ren Y, Nuttall JJ, Eley BS, Meyers TM, Smith PJ, Maartens G, McIlleron HM.

J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):439-43. doi: 10.1097/QAI.0b013e31819c33a3.

PMID:
19223781
17.

Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans.

Haas DW, Gebretsadik T, Mayo G, Menon UN, Acosta EP, Shintani A, Floyd M, Stein CM, Wilkinson GR.

J Infect Dis. 2009 Mar 15;199(6):872-80. doi: 10.1086/597125.

18.

A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations.

ter Heine R, Scherpbier HJ, Crommentuyn KM, Bekker V, Beijnen JH, Kuijpers TW, Huitema AD.

Antivir Ther. 2008;13(6):779-87.

PMID:
18839779
19.

Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.

López-Cortés LF, Ruiz-Valderas R, Viciana P, Alarcón-González A, Gómez-Mateos J, León-Jimenez E, Sarasanacenta M, López-Pua Y, Pachón J.

Clin Pharmacokinet. 2002;41(9):681-90.

PMID:
12126459
20.

Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients.

Yimer G, Ueda N, Habtewold A, Amogne W, Suda A, Riedel KD, Burhenne J, Aderaye G, Lindquist L, Makonnen E, Aklillu E.

PLoS One. 2011;6(12):e27810. doi: 10.1371/journal.pone.0027810. Epub 2011 Dec 6.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk